Latest topics page 33

Topics ordered by most recent activity across all 71 subcategories.

1,535 topics · page 33 of 52

Topic	Participants	Replies	Views	Activity
The nausea timeline across the first four weeks, with a tabulated log Practice › Side effects nausea fatigue vomiting The nausea timeline across the first four weeks, with a tabulated log — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in case the pattern…	+118	134	1.8k	10mo
Discussing something you have already been doing Clinical › Prescriber conversations prior authorisation type 2 diabetes beginner friendly telehealth Solved Under review On the subject in the title: Discussing something you have already been doing Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference and I…	+10	14	3.4k	10mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…		4	3.7k	10mo
Trial registration and comparing the protocol with the paper Evidence › Trials randomised trial open label intention to treat Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do…	+38	44	4.8k	10mo
Compounds this community declines to help with, and why Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…	+81	87	35k	10mo
Why catalogue breadth is not evidence of anything — what changed since Compounds › Other compounds custom synthesis mislabelling needs a source research use only Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+62	66	26k	10mo
Micronutrient adequacy at low total intake — does this still hold? Nutrition & Training › Protein & intake fatigue lean mass loss micronutrients constipation Solved Closed Micronutrient adequacy at low total intake — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Longitudinal report with the method stated, because…	+21	25	45k	10mo
Coming back to: Where the integrator drew the baseline, and how much it moved the number Analytics › HPLC & UHPLC peak integration gradient method UV & DAD detection data table On the subject in the title: Where the integrator drew the baseline, and how much it moved the number Working notes rather than a conclusion. Posting the method first, because I know what the first three…	+20	24	2.7k	10mo
An inter-laboratory comparison on one lot, tabulated Analytics › Method validation linearity LOD & LOQ precision & repeatability system suitability Closed On the subject in the title: An inter-laboratory comparison on one lot, tabulated Working notes rather than a conclusion. Working through the identity arithmetic and I would like it checked. semaglutide has a…		3	17k	10mo
Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP…		2	3.8k	10mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SELECT ( N Engl J Med ,…	+98	105	24k	10mo
When a tidy document is a signal and when it is decoration Analytics › COA interpretation certificate of analysis reference standards batch & lot numbers amino acid analysis When a tidy document is a signal and when it is decoration I have a specific reason for asking rather than idle curiosity, and the context is below. A documentation question rather than an analytical one. I…	+6	10	20k	10mo
Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? Evidence › Preprints preprint needs a source effect size Solved Under review The question in the title: Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen LEADER…	+103	115	24k	10mo
Reading a rodent study on a secretagogue without over-extrapolating Compounds › Secretagogues & GH axis observational data GHRP class CJC-1295 needs a source Closed Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of…	+50	54	32k	10mo
State-level differences that actually matter Regional › North America compounding telehealth insurance FDA Solved On the subject in the title: State-level differences that actually matter Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…	+6	10	56k	10mo
Coming back to: What happens when a maintainer goes quiet Documentation › Doc review promoted to docs citation check review date wiki post Asking directly, because I could not find a straight answer: What happens when a maintainer goes quiet Process question about how this site works. I have read the guidelines and the trust-level page and I…	+6	10	400	10mo
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
Deconvolution of a multiply charged envelope Analytics › Mass spectrometry MALDI-TOF charge states mass error (ppm) counter-ion content Closed Deconvolution of a multiply charged envelope — setting out what I have, and where I think it stops being reliable. Working through the identity arithmetic and I would like it checked. tirzepatide has a…		2	63	10mo
Needle changes between doses on a reusable pen Devices › Pens & autoinjectors subcutaneous injection dead volume missed dose storage Posting this under the heading it deserves: Needle changes between doses on a reusable pen Everything below is what sits behind that. I have read the maintained page on this and I still have a gap, so I am…	+34	38	1.5k	10mo
BPC-157: what the rodent literature actually shows, and what it does not Compounds › Repair & healing peptides observational data preprint BPC-157 needs a source BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a…	+44	48	3k	10mo
Revisiting: Reading a denial letter as a specification for your appeal Access › Insurance & coverage prior authorisation insurance formulary appeals Posting this under the heading it deserves: Revisiting: Reading a denial letter as a specification for your appeal Everything below is what sits behind that. A coverage question with the paperwork detail…	+125	138	9.4k	10mo
Revisiting: Why I ask for the gradient before I discuss the number Analytics › HPLC & UHPLC UV & DAD detection data table peak integration system suitability Posting this under the heading it deserves: Revisiting: Why I ask for the gradient before I discuss the number Everything below is what sits behind that. I would like to understand what this number means…	+15	19	43k	10mo
Reporting a disappointing outcome, and why it belongs here Outcomes › Progress reports data table DXA effect size Closed Reporting a disappointing outcome, and why it belongs here Writing it up because I had to work it out twice and would rather nobody else did. Longitudinal report with the method stated, because a number…	+21	29	62k	10mo
Washout: how long is long enough, and for what purpose Pharmacology › Pharmacokinetics semaglutide missed dose worked example Closed Washout: how long is long enough, and for what purpose — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in…	+63	70	13k	10mo
Why the timeline is on the right and not the left Meta › Site feedback moderation site feedback guidelines Solved Why the timeline is on the right and not the left — that is the question, and I have not found it answered plainly anywhere I have looked. Nominating something for promotion into the documentation commons.…	+67	73	19k	10mo
Journal club: STEP-HFpEF and symptom endpoints — a second dataset Evidence › Journal club estimand risk of bias randomised trial journal club On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with STEP 4 ( JAMA , 2021) and…	+11	15	4k	10mo
Coming back to: Oxidation and deamidation mass shifts, tabulated Analytics › Mass spectrometry LC-MS charge states MALDI-TOF high-resolution MS Oxidation and deamidation mass shifts, tabulated — setting out what I have, and where I think it stops being reliable. Working through the identity arithmetic and I would like it checked. retatrutide has a…	+34	38	4.8k	10mo
Payment method and the leverage it gives you, ranked Sourcing › Payments research use only payments documentation quality Solved Closed Posting this under the heading it deserves: Payment method and the leverage it gives you, ranked Everything below is what sits behind that. Structured report rather than an opinion, following the format the…	+71	76	56k	10mo
GIP receptor agonism and the argument about direction Pharmacology › Receptor biology tirzepatide long read amylin analogues semaglutide GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise…		2	867	10mo
Hypertension improvement and when medication needs revisiting Clinical › Comorbidities type 2 diabetes MASH / hepatic steatosis chronic kidney disease Closed Hypertension improvement and when medication needs revisiting Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…	+74	79	1.1k	10mo